GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Pronged antibody tested to shrink tumors before stomach cancer surgery
Disease control Not yet recruitingThis study is testing whether a new drug called zanidatamab, when combined with standard chemotherapy, can shrink tumors in patients with a specific type of stomach or gastroesophageal junction (GEJ) cancer before they have surgery. The trial will enroll about 30 adults with loca…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo trial offers hope for advanced stomach, colon & pancreatic cancers
Disease control Not yet recruitingThis study is testing whether adding an experimental drug called SSGJ-706 to standard first-line chemotherapy is safe and more effective for treating advanced cancers of the digestive system. It will enroll 300 adults with advanced stomach, colorectal, pancreatic, or esophageal c…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo targets tough stomach and pancreatic cancers
Disease control Not yet recruitingThis study is testing a new drug combination called IBI343 for people with advanced stomach or pancreatic cancer that has a specific marker called CLDN18.2. The main goals are to see if the treatment is safe and if it helps shrink tumors. It will enroll about 389 adults who have …
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Doctors test best drug combo to keep stomach cancer from coming back after surgery
Disease control Not yet recruitingThis study aims to find the best drug treatment to prevent cancer from returning after stomach cancer surgery. It will compare two different drug combinations in 500 patients who already had chemotherapy and immunotherapy before their surgery and had no visible cancer left after …
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Liaoning Cancer Hospital & Institute • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Blood test could spare stomach cancer patients from unnecessary chemo
Disease control Not yet recruitingThis study is testing a new approach for treating stomach cancer. After surgery, a blood test will check for tiny traces of leftover cancer. The goal is to see if patients with a clean blood test can safely skip the usual harsh chemotherapy, avoiding its severe side effects, with…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists hunt clues to unlock stomach Cancer's immune resistance
Disease control Not yet recruitingThis study aims to understand why some patients with a specific type of stomach cancer respond well to immunotherapy while others do not. It will enroll 15 Asian patients with this cancer type who are scheduled for surgery after receiving immunotherapy. The goal is to learn what …
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New stomach cancer treatment trial tests easier injection method
Disease control Not yet recruitingThis study is testing whether giving the immunotherapy drug AK104 as a simple injection under the skin works as well as giving it through an IV when combined with standard chemotherapy for advanced stomach cancer. The trial will enroll 422 people with advanced stomach or gastroes…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC